The White House's budget request for fiscal 2019 would increase FDA discretionary funding by $473 million, with much of the additional funding intended to advance the availability of innovative drugs and medical devices and to develop regulatory science tools for reducing opioid-drug misuse and abuse. The funding boost is "a recognition that the agency is doing its job well and making a critical public health difference," said Alliance for a Stronger FDA Executive Director Ladd Wiley.
White House budget would boost FDA's ability to respond to opioid crisis
Sign up for ANA SmartBrief
Nursing news and information
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.